EVX‑03 had long been highlighted as a promising next‑generation DNA‑based cancer vaccine and was initially intended to be evaluated in non‑small cell lung cancer. However, the planned clinical trial never materialized, and Evaxion now announces that the project has been terminated and removed from the company’s pipeline.
Evaxion drops solid tumour vaccine to advance new glioblastoma program
Danish biotech company Evaxion is discontinuing a vaccine candidate for solid tumors and redirecting resources to a program specifically aimed at brain cancer.
Advertisement
BREAKING